Cogent Biosciences (COGT) Equity Average (2018 - 2021)
Historic Equity Average for Cogent Biosciences (COGT) over the last 4 years, with Q3 2021 value amounting to $205.0 million.
- Cogent Biosciences' Equity Average rose 1408029.32% to $205.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $205.0 million, marking a year-over-year increase of 1408029.32%. This contributed to the annual value of $133.2 million for FY2020, which is 18960.93% up from last year.
- Per Cogent Biosciences' latest filing, its Equity Average stood at $205.0 million for Q3 2021, which was up 1408029.32% from $219.8 million recorded in Q2 2021.
- Cogent Biosciences' 5-year Equity Average high stood at $230.7 million for Q1 2021, and its period low was -$55.1 million during Q1 2018.
- Its 4-year average for Equity Average is $70.9 million, with a median of $44.5 million in 2019.
- Its Equity Average has fluctuated over the past 5 years, first crashed by 10428.92% in 2020, then skyrocketed by 1408029.32% in 2021.
- Quarter analysis of 4 years shows Cogent Biosciences' Equity Average stood at $63.9 million in 2018, then crashed by 52.74% to $30.2 million in 2019, then skyrocketed by 251.9% to $106.2 million in 2020, then surged by 92.97% to $205.0 million in 2021.
- Its Equity Average stands at $205.0 million for Q3 2021, versus $219.8 million for Q2 2021 and $230.7 million for Q1 2021.